FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression.
Click to find out more

Updated information on XTANDI (enzalutamide) for the treatment of people with metastatic castration-resistant prostate cancer.
Click to find out more

FDA Approves Genentech’s TECENTRIQ (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial cell carinoma.
TECENTRIQ Package Insert
Click to find out more

FDA Approves Genentech’s VENCLEXTA™ (venetoclax) for the treatment of people with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received one prior therapy.
Venclexta Package Insert

FDA Approves Genentech’s GAZYVA® (obinutuzumab) in combination with bendamustine followed by GAZYVA monotherapy for the treatment of people with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen.
Gazyva Package Insert
Click to find out more

FDA Approves Expanded Indication of Pfizer Oncology’s IBRANCE® (palbociclib) in combination with Fulvestrant.
Click to find out more

FDA Approves New indication for Merck’s EMEND® (fosaprepitant dimeglumine)
Click to find out more

FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma
Click to find out more

FDA Approves ALECENSA® (alectinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. 
Click to find out more

FDA Approves  NINLARO® (ixazomib) in combination with lenalideomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Click to find out more

FDA Approves Cotellic (Cobimetinib) in Combination With Zelboraf (Vemurafenib) in Advanced Melanoma
Click to find out more

FDA Approves new Indication for Keytruda (pembrolizumab)
Click to find out more